As of today the participating centers have recruited two-thirds of the target number. We expect EoT at the end of this year and would like to thank all of the involved researchers and their study teams for their enthusiasm and motivation. This research is linking next level microbiome diagnostics with precision medicine and will aid to unlock the full potential of cancer immunotherapy.
BiomeOne is a clinical research project in the field of cancer immunotherapy. The goal of the study is to develop a biomarker based on the intestinal microbiome of cancer patients that allows to predict tumor response to immune-checkpoint-inhibitors prior to treatment start.
